This observational study was conducted in healthy premenopausal women, who presented themselves for contraception with an intrauterine system (IUS) releasing LNG (6 mcg/d) (Jaydess®, Bayer, Germany) at the outpatient Family Planning Clinics of the Departments of Obstetrics and Gynaecology of the Universities of Cagliari and Sassari (CA/SS), University-Hospitals of CA/SS (Italy). After a screening visit, 31 women without contraindications to Jaydess® were included in the study. No difficulty in Jaydess® insertion (Ji) was found in 87% of subjects, with pelvic pain (PP) (visual analogic scale, VAS:5.33 ± 2.54) reported by 27/31 subjects at the Ji. Pelvic pain was reported by 17/31 subjects on the first day (VAS: 3.07 ± 3.1), 16/31 subjects on the second day (VAS:2.37 ± 2.71), and 11/31 subjects on the third day (VAS:1.18 ± 2.02) from Ji, with a significant (p < .001) decrease in the intensity. The primary purposes of the study were to evaluate whether a 12-month-treatment (12-M-T) with Jaydess® interferes on either the quality of life (QoL) or sexuality. Jaydess® did not modify either QoL or sexuality in the 25 subjects who completed the 12-M-T. Throughout the 12-M-T, PP, or pregnancies were not found; the menstrual blood loss was significantly (p < .0001) reduced, and the intensity VAS of dysmenorrhea (#14 subjects) significantly (p < .001) improved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590.2017.1416465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prenatal human brain development is not spared by IUGR: A systematic review.
Early Hum Dev
January 2025
School of Medicine, Atenas University Centre, Prefeito Alberto Moura, 6000, 35701-383 Sete Lagoas, MG, Brazil. Electronic address:
Background: Intrauterine growth restriction (IUGR) is a severe condition in which the fetus fails to reach its genetically predetermined growth potential, impairing prenatal development and predisposing individuals to postnatal consequences that may persist into adulthood. Although fetal mechanisms such as the brain-sparing effect have been proposed to protect the brain against IUGR-related deficits, the extent of this protection remains unclear.
Objective: To conduct a systematic review that demonstrates prenatal morphofunctional abnormalities in the brain of individuals with IUGR.
Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
J Natl Cancer Inst
January 2025
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
Background: Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.
Methods: We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).
The Fetal Environment and the Development of Hypertension-The Epigenetic Modification by Glucocorticoids.
Int J Mol Sci
January 2025
Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare, Otawara 324-8501, Japan.
Intrauterine growth restriction (IUGR) is a risk factor for postnatal cardiovascular, metabolic, and psychiatric disorders. In most IUGR models, placental dysfunction that causes reduced 11β-hydroxysteroid dehydrogenase 2 (11βHSD2) activity, which degrades glucocorticoids (GCs) in the placenta, resulting in fetal GC overexposure. This overexposure to GCs continues to affect not only intrauterine fetal development itself, but also the metabolic status and neural activity in adulthood through epigenetic changes such as microRNA change, histone modification, and DNA methylation.
View Article and Find Full Text PDFSafety and efficacy of the initial application of vacuum-induced intrauterine tamponade for the management of postpartum hemorrhage.
Taiwan J Obstet Gynecol
January 2025
Department of Fetal-Maternal Medicine, Obstetrics, Gifu Prefectural General Medical Center, 4-6-1 No-isshiki, Gifu City 500-8717, Gifu, Japan.
Objective: This study aimed to evaluate the safety and efficacy of vacuum-induced intrauterine balloon tamponade (vIBT) using the modified Bakri system in a clinical setting.
Materials And Methods: This single-center observational study included women who had undergone vIBT for primary postpartum hemorrhage (PPH). Vacuum induction at 60 kPa in the uterus was continued for 1 h with 50-100 ml saline, and the balloon was promptly removed after the protocol was completed.
National assessment on the frequency of pain medication prescribed for intrauterine device insertion procedures within the Veterans Affairs Health Care System.
PLoS One
January 2025
US Department of Veterans Affairs, Palo Alto Healthcare System, National Center for Collaborative Healthcare Innovation, Palo Alto, California, United States of America.
Background: The intrauterine device (IUD) is a highly effective form of long-acting reversible contraception, widely recognized for its convenience and efficacy. Despite its benefits, many patients report moderate to severe pain during and after their IUD insertion procedure. Furthermore, reports suggest significant variability in pain control medications, including no adequate pain medication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!